Omega Diagnostics rules out a placing as it has plenty of cash

Omega Diagnostics has categorically dismissed placing rumours by reassuring investors that it has plenty of cash within its operations, even after the significant scaling up of its manufacturing capacity to be able to produce 2 million lateral flow tests per week by the end of April.

In a promising development for investors, Omega Diagnostics confidently tweeted:

“It’s worth pointing out that even after *considerable* investment in our scaled-up production capacity, year-end (i.e. 31 March 2021) cash is expected to be in the region of £5.5-£6m.

Let’s put those placing rumours to bed. For good.”

Now all investors will be hoping for is some firm numbers on the scale of the opportunity that awaits the diagnostics specialist.

Recently it noted that the government had earmarked £374m in its budget for Omega Diagnostics, although there was no certainty as to the amount that may or not be awarded.

Today the business also give a further boost to investors as it announced that commercial partner Mologic has had its lateral antigen flow test CE-marked for professional use under Omega’s VISITECT brand.

Let's Talk

Argo & NasdaqThink Peter Wall gave it away in those answers. There is literally … Read More
Omega very bullishNever heard Colin so bullish before, he definitely knows good time … Read More
Getting into CBD stocksThanks I'm going to wait for MXC to dip a bit more big overra … Read More
Argo Blockchain Share Price Predi …Update. I'm not into even more profit. Am holding unless Bitc … Read More
ODX target price is?People obviously wanted to see we have a £200m contract in the bag … Read More
Hey, profit awaits! Free Sharebuyers Newsletter

Receive hot tips you can profit from - only sent when it matters. Twitter: @ShareBuyers.

error: ShareBuyers content is protected